Skip to main content
Top
Published in: BMC Neurology 1/2017

Open Access 01-12-2017 | Research article

Looking beyond the brain to improve the pathogenic understanding of Parkinson’s disease: implications of whole transcriptome profiling of Patients’ skin

Authors: Anu Planken, Lille Kurvits, Ene Reimann, Liis Kadastik-Eerme, Külli Kingo, Sulev Kõks, Pille Taba

Published in: BMC Neurology | Issue 1/2017

Login to get access

Abstract

Background

Parkinson’s Disease is a progressive neurodegenerative disease, characterized by symptoms of motor impairment, resulting from the loss of dopaminergic neurons in the midbrain, however non-neuronal symptoms are also common. Although great advances have been made in the pathogenic understanding of Parkinson’s Disease in the nervous system, little is known about the molecular alterations occurring in other non-neuronal organ systems. In addition, a higher rate of melanoma and non-melanoma skin cancer has been observed in the Parkinson’s Disease population, indicating crosstalk between these diseases.

Methods

To understand the molecular pathogenesis and gene expression alterations of Parkinson’s Disease in peripheral tissues, and in order to explore the possible link between skin cancer and neurodegeneration, whole transcriptomic profiling of patients’ skin was performed. Skin biopsies from 12 patients and matched controls were collected, and processed with high-throughput RNA-sequencing analysis.

Results

This analysis resulted in a large collection of over 1000 differentially expressed genes, among which clear biological and functional networks could be distinguished. The central functional processes altered in patients skin can be grouped into six broad categories: impaired cellular metabolism and mitochondrial dysfunction, defective protein metabolism, disturbed skin homeostasis, dysfunctional nuclear processes, altered signalling and tumour pathways, as well as disordered immune regulation.

Conclusions

These results demonstrate that the molecular alterations leading to neurodegeneration in the CNS are systemic and manifest also in peripheral tissues, thereby indicating the presence of “skin-brain” crosstalk in Parkinson’s Disease. In addition, the extensive homeostatic imbalance and basal stress can lead to increased susceptibility to external and internal mutagenic hazards in these patients, and thus provide a possible molecular link for the crosstalk between skin cancer and Parkinson’s Disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S1–5.CrossRefPubMed Dickson DW, Fujishiro H, Orr C, DelleDonne A, Josephs KA, Frigerio R, Burnett M, Parisi JE, Klos KJ, Ahlskog JE. Neuropathology of non-motor features of Parkinson disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S1–5.CrossRefPubMed
2.
go back to reference Wolters E. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S6–12.CrossRefPubMed Wolters E. Non-motor extranigral signs and symptoms in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15 Suppl 3:S6–12.CrossRefPubMed
3.
go back to reference Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson’s disease. Movement Disorders. 2009;24(6):793–800.CrossRefPubMed Djaldetti R, Lev N, Melamed E. Lesions outside the CNS in Parkinson’s disease. Movement Disorders. 2009;24(6):793–800.CrossRefPubMed
4.
go back to reference AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11(1):6–23.CrossRefPubMed AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics. 2014;11(1):6–23.CrossRefPubMed
5.
go back to reference Robinson PA. Understanding the molecular basis of Parkinson’s disease, identification of biomarkers and routes to therapy. Expert Rev Proteomics. 2010;7(4):565–78.CrossRefPubMed Robinson PA. Understanding the molecular basis of Parkinson’s disease, identification of biomarkers and routes to therapy. Expert Rev Proteomics. 2010;7(4):565–78.CrossRefPubMed
6.
go back to reference Beitz JM. Skin and wound issues in patients with Parkinson’s disease: an overview of common disorders. Ostomy Wound Manage. 2013;59(6):26–36.PubMed Beitz JM. Skin and wound issues in patients with Parkinson’s disease: an overview of common disorders. Ostomy Wound Manage. 2013;59(6):26–36.PubMed
7.
go back to reference Doppler K, Ebert S, Uceyler N, Trenkwalder C, Ebentheuer J, Volkmann J, Sommer C. Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta neuropathologica 2014;128(1):99–109.CrossRefPubMedPubMedCentral Doppler K, Ebert S, Uceyler N, Trenkwalder C, Ebentheuer J, Volkmann J, Sommer C. Cutaneous neuropathy in Parkinson's disease: a window into brain pathology. Acta neuropathologica 2014;128(1):99–109.CrossRefPubMedPubMedCentral
9.
go back to reference Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C. Skin cancer and Parkinson’s disease. Movement Disorders. 2010;25(2):139–48.CrossRefPubMed Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C. Skin cancer and Parkinson’s disease. Movement Disorders. 2010;25(2):139–48.CrossRefPubMed
10.
go back to reference Inzelberg R, Israeli-Korn SD. The particular relationship between Parkinson’s disease and malignancy: a focus on skin cancers. J Neural Transm. 2009;116(11):1503–7.CrossRefPubMed Inzelberg R, Israeli-Korn SD. The particular relationship between Parkinson’s disease and malignancy: a focus on skin cancers. J Neural Transm. 2009;116(11):1503–7.CrossRefPubMed
12.
go back to reference Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology. 2006;17(5):582–7.CrossRefPubMed Olsen JH, Friis S, Frederiksen K. Malignant melanoma and other types of cancer preceding Parkinson disease. Epidemiology. 2006;17(5):582–7.CrossRefPubMed
13.
go back to reference Paisan-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology. 2010;75(18):1653–5.CrossRefPubMed Paisan-Ruiz C, Houlden H. Common pathogenic pathways in melanoma and Parkinson disease. Neurology. 2010;75(18):1653–5.CrossRefPubMed
14.
go back to reference Devine MJ, Plun-Favreau H, Wood NW. Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer. 2011;11(11):812–23.CrossRefPubMed Devine MJ, Plun-Favreau H, Wood NW. Parkinson’s disease and cancer: two wars, one front. Nat Rev Cancer. 2011;11(11):812–23.CrossRefPubMed
15.
go back to reference Herrero Hernandez E. Pigmentation genes link Parkinson’s disease to melanoma, opening a window on both etiologies. Med Hypotheses. 2009;72(3):280–4.CrossRefPubMed Herrero Hernandez E. Pigmentation genes link Parkinson’s disease to melanoma, opening a window on both etiologies. Med Hypotheses. 2009;72(3):280–4.CrossRefPubMed
16.
go back to reference Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52.CrossRefPubMedPubMedCentral Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988;51(6):745–52.CrossRefPubMedPubMedCentral
18.
go back to reference Fahn S ER, UPDRS Development Committee. : Unified Parkinson’s disease rating scale. Recent developments in Parkinson’s disease Florham Park, NJ: Mac-Millan Healthcare Information 1987, Vol 2.:153–163 Fahn S ER, UPDRS Development Committee. : Unified Parkinson’s disease rating scale. Recent developments in Parkinson’s disease Florham Park, NJ: Mac-Millan Healthcare Information 1987, Vol 2.:153–163
19.
go back to reference Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disorders. 2008;23(15):2129–70.CrossRefPubMed Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Movement Disorders. 2008;23(15):2129–70.CrossRefPubMed
20.
21.
go back to reference Schwab RS EAIGF, Donaldson IML, eds. Third Symposium on Surgery in Parkinson’s disease. Edinburgh: Livingstone, :152–7.: Projection technique for evaluating surgery in Parkinson’s disease. In: Third Symposium on Surgery in Parkinson’s disease 1969; Edinburgh: Livingstone; 1969: 152–157 Schwab RS EAIGF, Donaldson IML, eds. Third Symposium on Surgery in Parkinson’s disease. Edinburgh: Livingstone, :152–7.: Projection technique for evaluating surgery in Parkinson’s disease. In: Third Symposium on Surgery in Parkinson’s disease 1969; Edinburgh: Livingstone; 1969: 152–157
22.
go back to reference Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMed Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–98.CrossRefPubMed
24.
go back to reference Ruiperez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res. 2010;49(4):420–8.CrossRefPubMed Ruiperez V, Darios F, Davletov B. Alpha-synuclein, lipids and Parkinson's disease. Prog Lipid Res. 2010;49(4):420–8.CrossRefPubMed
25.
go back to reference Austin S, St-Pierre J. PGC1alpha and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci. 2012;125(Pt 21):4963–71.CrossRefPubMed Austin S, St-Pierre J. PGC1alpha and mitochondrial metabolism--emerging concepts and relevance in ageing and neurodegenerative disorders. J Cell Sci. 2012;125(Pt 21):4963–71.CrossRefPubMed
26.
go back to reference Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2(52):52ra73.CrossRefPubMedPubMedCentral Zheng B, Liao Z, Locascio JJ, Lesniak KA, Roderick SS, Watt ML, Eklund AC, Zhang-James Y, Kim PD, Hauser MA, et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci Transl Med. 2010;2(52):52ra73.CrossRefPubMedPubMedCentral
27.
go back to reference Parlato R, Liss B. How Parkinson's disease meets nucleolar stress. Biochim Biophys Acta. 2014;1842(6):791–7.CrossRefPubMed Parlato R, Liss B. How Parkinson's disease meets nucleolar stress. Biochim Biophys Acta. 2014;1842(6):791–7.CrossRefPubMed
28.
29.
go back to reference Lim X, Nusse R. Wnt signaling in skin development, homeostasis, and disease. Cold Spring Harb Perspect Biol 2013;5(2):1–25.CrossRef Lim X, Nusse R. Wnt signaling in skin development, homeostasis, and disease. Cold Spring Harb Perspect Biol 2013;5(2):1–25.CrossRef
Metadata
Title
Looking beyond the brain to improve the pathogenic understanding of Parkinson’s disease: implications of whole transcriptome profiling of Patients’ skin
Authors
Anu Planken
Lille Kurvits
Ene Reimann
Liis Kadastik-Eerme
Külli Kingo
Sulev Kõks
Pille Taba
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2017
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-016-0784-z

Other articles of this Issue 1/2017

BMC Neurology 1/2017 Go to the issue